Parametric mapping of 5HT1A receptor sites in the human brain with the hypotime method: Theory and normal values

Journal of Nuclear Medicine

Volumn 50, Issue 8, 2009, Pages 1229-1236

  Møller, Mette ^a   Rodell, Anders ^b   Gjedde, Albert ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

11C WAY 100635; Hypotime; Neurotransmission; PET; Serotonin 5HT1A receptors

Indexed keywords

CARBON 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; RADIOLIGAND; SEROTONIN 1A RECEPTOR; TRACER; UNCLASSIFIED DRUG; DESMETHYL WAY 100635; DESMETHYL-WAY 100635; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN CIRCULATION; BRAIN MAPPING; BRAIN TISSUE; CEREBELLUM; DRUG ACCUMULATION; DRUG BINDING; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOTIME METHOD; MALE; MATHEMATICAL COMPUTING; MULTILINEARIZED REFERENCE TISSUE METHOD; NORMAL HUMAN; PARAMETRIC TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; REGRESSION ANALYSIS; RELIABILITY; TEMPORAL LOBE; ALGORITHM; BRAIN; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; REFERENCE VALUE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ADULT; AGED; ALGORITHMS; BRAIN; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT1A; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 68249153265     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.053322     Document Type: Article

References (27)

1. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174-180.
2. Tiihonen J, Keski-Rahkonen A, Lopponen M, et al. Brain serotonin 1A receptor binding in bulimia nervosa. Biol Psychiatry. 2004;55:871-873.
3. 11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain. 2005;128: 896-905.
4. 11C]WAY-100635. Arch Gen Psychiatry. 2002;59:514-520.
5. 11C-WAY 100635 PET study. Neurology. 2003;60:601-605.
6. 1A receptor binding in human temporal lobe epilepsy. Neurology. 2004;62:1343-1351.
7. 1A receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage. 2002;15:620-632.
8. 11C]WAY-100635: considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab. 2007;27: 185-195.
9. 1A receptor sites in human brain as function of age in healthy humans. Neuropsychopharmacology. 2007;32:1707-1714.
10. 1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res. 2002;954:173-182.
11. 11C]WAY-100635 and PET. Neuropsychopharmacology. 2001;24:522-530.
12. 11C]WAY-100635. Mol Psychiatry. 2004;9:386-392.
13. IA receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. Synapse. 2001;41:150-159.
14. 11C]WAY-100635: effect of endogenous serotonin. Synapse. 2001; 40:122-129.
15. 11C]WAY-100635 for PET. Neuroimage. 1998;8: 426-440.
16. 11C]WAY-100635: explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl Med Biol. 1998;25:215-223.
17. 11C]WAY-100635. Brain Res. 1997;745:96-108.
18. 1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab. 2005;25:785-793.
19. Zhou Y, Endres CJ, Brasic JR, Huang SC, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage. 2003;18:975-989.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
21. 11Ccarboxylation of an immobilized Grignard reagent. J Labelled Comp Radio-pharm. 1996;38:941-953.
22. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192-205.
23. Gjedde A. Modelling metabolite and tracer kinetics. In: Feinendegen LE, Shreeve WW, Eckelman WC, Bahk Y-W, Wagner HN Jr, eds. Molecular Nuclear Medicine. Berlin, Germany: Springer-Verlag; 2003:121-169.
24. Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos Trans R Soc Lond. 1825;115:513-583.
25. Whitaker-Azmitia PM. Serotonin and brain development: role in human developmental diseases. Brain Res Bull. 2001;56:479-485.
26. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.
27. Ridley RM, Harder JA, Baker HF. Neurochemical modulation of the hippocampus in learning, remembering and forgetting in primates. Neurodegeneration. 1996;5:467-471.